Le Lézard
Classified in: Science and technology
Subject: ATY

Rosen Law Firm Reminds Vuzix Corporation Investors of Important September 24 Deadline In Class Action- VUZI


NEW YORK, Sept. 20, 2018 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Vuzix Corporation (NASDAQ: VUZI): (i) pursuant and/or traceable to Vuzix's registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Vuzix's January 2018 secondary public offering; and/or (ii) between November 9, 2017 and March 20, 2018, inclusive (the "Class Period") of the important September 24, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Vuzix investors under the federal securities laws.

Rosen Law Firm, P.A. Logo

To join the Vuzix class action, go to https://www.rosenlegal.com/cases-1306.html or call Phillip Kim, Esq. or Zachary Halper, Esq. toll-free at 866-767-3653 or email [email protected] or  [email protected] for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION.  UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Vuzix used unlawful stock promotion tactics to boost its stock price; (2) Vuzix used misleading stock promotion tactics to raise nearly $30 million at an all-time high share price; and (3) as a result of the foregoing, defendants' statements in the Registration Statement regarding Vuzix's business, operations, and prospects, were materially false and/or misleading. When the true details entered the market, the lawsuit claims that investors suffered damages

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 24, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to https://www.rosenlegal.com/cases-1306.html to join the class action. You may also contact Phillip Kim or Zachary Halper of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      Zachary Halper, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 34th Floor
      New York, NY  10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

 

SOURCE Rosen Law Firm, P.A.


These press releases may also interest you

at 10:45
The "PCR Markets. Forecasts for qPCR, dPCR, Singleplex & Multiplex Markets and by Application, Product and Place. With Executive and Consultant Guides, Including Customized Forecasting and Analysis. 2023 to 2027" report has been added to...

at 10:31
Gulfstream Aerospace Corp., a wholly owned subsidiary of General Dynamics , today announced the all-new Gulfstream G700 has received Federal Aviation Administration (FAA) type certification, paving the way for customer deliveries of the most spacious...

at 10:30
The "Licensing Deals in Biotechnology 2019-2024" report has been added to ResearchAndMarkets.com's offering. Licensing Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter licensing deals. Fully...

at 10:30
The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. Exciting technical...

at 10:30
RIVANNA®, a developer of imaging-based medical solutions, names Craig Loomis as senior director of product management. With over 25 years of extensive experience in global product development and commercialization within the healthcare sector, Mr....

at 10:15
The Micro-electro-mechanical System (MEMS) market is projected to grow from USD 16.5 billion in 2024 and is estimated to reach USD 24.2 billion by 2029; it is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.9% from 2024 to 2029...



News published on and distributed by: